MALE HYPOGONADISM:
AS REPLACEMENT THERAPY, I.E., FOR EUNUCHISM, THE SUGGESTED DOSAGE IS 50 TO 400 MG EVERY 2 TO 4 WEEKS.
IN MALES WITH DELAYED PUBERTY:
VARIOUS DOSAGE REGIMENS HAVE BEEN USED; SOME CALL FOR LOWER DOSAGES INITIALLY WITH GRADUAL INCREASES AS PUBERTY PROGRESSES, WITH OR WITHOUT A DECREASE TO MAINTENANCE LEVELS. OTHER REGIMENS CALL FOR HIGHER DOSAGE TO INDUCE PUBERTAL CHANGES AND LOWER DOSAGE FOR MAINTENANCE AFTER PUBERTY. THE CHRONOLOGICAL AND SKELETAL AGES MUST BE TAKEN INTO CONSIDERATION, BOTH IN DETERMINING THE INITIAL DOSE AND IN ADJUSTING THE DOSE. DOSAGE IS WITHIN THE RANGE OF 50 TO 200 MG EVERY 2 TO 4 WEEKS FOR A LIMITED DURATION, FOR EXAMPLE, 4 TO 6 MONTHS. X-RAYS SHOULD BE TAKEN AT APPROPRIATE INTERVALS TO DETERMINE THE AMOUNT OF BONE MATURATION AND SKELETAL DEVELOPMENT
PALLIATION OF INOPERABLE MAMMARY CANCER IN WOMEN:
A DOSAGE OF 200 TO 400 MG EVERY 2 TO 4Β WEEKS IS RECOMMENDED. WOMEN WITH METASTATIC BREAST CARCINOMA MUST BE FOLLOWED CLOSELY BECAUSE ANDROGEN THERAPY OCCASIONALLY APPEARS TO ACCELERATE THE DISEASE.